At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 69 enrolled
Drug / intervention
KZR-616drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2 Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis (MISSION)
In Brief
A Phase 2 clinical trial evaluating KZR-616 for Lupus Nephritis and Systemic Lupus Erythematosus. Completed, enrolled 69 participants across 36 sites in 8 countries.
Detailed Summary
This was a Phase 1b/2, multi-center study in which patients received KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLupus Nephritis, Systemic Lupus Erythematosus
CountriesAustralia, Colombia, Mexico, Peru, Poland, Russia, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartFeb 2018
Primary CompletionAug 2022
TodayJul 2026
First PostedJan 8, 2018
Enrollment StartFeb 20, 2018
Primary CompletionAug 4, 2022
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 8.5 years ago
Interventions
KZR-616drug
Subcutaneous Injection of KZR-616